1. Patent Highlights August–September 2018
   Hermann AM Mucke, 2019, Pharmaceutical Patent Analyst CrossRef
2. Hematopoietic Progenitor Kinase 1 in Tumor Immunology: A Medicinal Chemistry Perspective
   Qiangsheng Zhu et al, 2022, Journal of Medicinal Chemistry CrossRef
3. The development of small-molecule inhibitors targeting HPK1
   Lixin Zhou et al, 2022, European Journal of Medicinal Chemistry CrossRef
4. MAP4K1 functions as a tumor promotor and drug mediator for AML via modulation of DNA damage/repair system and MAPK pathway
   Qing Ling et al, 2021, eBioMedicine CrossRef
5. Current strategies for targeting HPK1 in cancer and the barriers to preclinical progress
   Hui Chen et al, 2024, Expert Opinion on Therapeutic Targets CrossRef
6. Hematopoietic progenitor kinase 1 inhibits the development and progression of pancreatic intraepithelial neoplasia
   Hua Wang et al, 2023, Journal of Clinical Investigation CrossRef
7. Mitogen-Activated Protein Kinase Inhibitors and T-Cell-Dependent Immunotherapy in Cancer
   Sandeep Kumar et al, 2020, Pharmaceuticals CrossRef